Content Exchange

NOTTINGHAM, England and MORRISVILLE, N.C., Aug. 2, 2021 /PRNewswire/ -- Calyx, the eClinical and Regulatory solutions and services provider most relied on for solving complex data challenges in clinical research, today announced that Craig M. Mooney has joined the company as Vice President of Science and e-Tech Enabled Services. Mooney has nearly 30 years' experience in the clinical development industry, with concentrated focus on optimizing IRT to improve clinical trial efficiencies.

Craig's understanding of IRT from a delivery and user perspective will benefit Calyx's global pharma and CRO clients

"Craig brings a unique understanding of IRT from both a delivery and user perspective, which we believe will be a great benefit to our global pharmaceutical and CRO clients," said Dr. Stephen Bravo, Chief Medical Officer of Calyx. "We're delighted to have him join our team."

Mooney comes to Calyx from Bristol-Myers Squibb, where he served as the Director of IRT for most of the past decade. In his role at Calyx, he will shape the company's eClinical technology development pipeline and consult with its customers on optimizing IRT to improve operational efficiencies and meet study and regulatory requirements.

"Since Calyx became its own entity, I've watched them aggressively invest in hiring experts with well-honed skills and fresh viewpoints to ensure their solutions and services meet the needs of the industry," said Mooney. "I see the company as the perfect blend of entrepreneurial creativity and the expertise that only comes with a long history of experience and success, and I'm thrilled to join the team."

Visit for more information.

About Calyx

Through innovative eClinical and Regulatory solutions and services, Calyx turns the uncertain into the reliable, helping bring new medical treatments to market reliably. With deep expertise in clinical development and more than 25 years supporting trial sponsors and clinical research organizations, Calyx harnesses its intelligence and experience to solve complex problems, deliver fast insights, and get new drugs to market every day.

Take your trials further, with intelligent insights at or at LinkedIn, Twitter, or Facebook.


This article originally ran on

You must be logged in to react.
Click any reaction to login.
0 Content Exchange
Load comments

Thank you for reading!

Please purchase a subscription to read our premium content. If you have a subscription, please log in or sign up for an account on our website to continue.